Generic Latisse is bimatoprost 0.03%, the same active ingredient at the same strength as brand Latisse, the prescription eyelash treatment made by AbbVie. Careprost is an Indian version: a 3 mL bottle of bimatoprost 0.03% made by Sun Pharma. This page lists every bimatoprost 0.03% lash product SafeRxPills sells to customers in the United States, with the price per bottle and per mL taken from our live catalogue, and sets out what a US buyer should know before ordering Careprost or another generic Latisse online: what the Latisse label says about use and results, who should not use it, what the FDA says about importing medicines, and how payment, shipping and delivery work on this site.
The products on this page are Indian bimatoprost brands. They are not FDA-approved products, and bimatoprost is a prescription medicine in the US. If you want the full product comparison first, read Careprost vs Latisse; this page is about buying.
Careprost and generic Latisse: the short version
- What you get: a 3 mL bottle of bimatoprost 0.03% solution from an Indian brand owner (Sun Pharma, Intas or Actiza).
- Price: Careprost costs $9.00 a bottle; the lowest price per bottle across our lash products is $5.00 (Lashona, 100 bottles for $500.00). Catalogue prices on 30 October 2026, before shipping.
- How it is used: the Latisse label says one drop on a sterile single-use applicator, once nightly, along the upper eyelid margin only, with a new applicator for each eye.
- Results: in the trial behind the Latisse approval, 78% of adults had at least a 1-grade improvement in overall lash prominence at week 16, against 18% on the inactive solution.
- Check first if: you use any eye-pressure (glaucoma) drops, especially prostaglandin drops such as Lumigan, latanoprost or travoprost, or have ever had abnormal eye pressure. The label says to use Latisse only under the close supervision of your doctor.
- Shipping to the US: $25 flat, free on orders of $149 or more, 7 to 14 business days, with tracking.
- The law: the FDA says that in most circumstances it is illegal for individuals to import drugs into the US for personal use. Read the import section below before you order.
What generic Latisse is
Latisse (bimatoprost ophthalmic solution) 0.03% is indicated, in the words of its US label, "to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness." Hypotrichosis means having too few or too short lashes. Drugs@FDA lists the Latisse application (NDA 022369) as approved on 24 December 2008, as a prescription product.
The FDA has also approved generic bimatoprost 0.03% topical solutions for the lashes. openFDA lists four abbreviated applications: Sandoz (ANDA 202719, approved 19 April 2016) and Alembic (ANDA 210515, approved 21 January 2020), both listed as prescription products, and Apotex (ANDA 201894) and Hikma (ANDA 203051), both listed as discontinued. The Sandoz and Alembic eyelash solutions also appear in the October 2026 Medicaid pharmacy cost survey, so they are bought by US pharmacies.
Careprost and the other brands on this page are a different thing: Indian bimatoprost 0.03% products, made in India and not approved by the FDA. "Generic Latisse" is the common search term for both kinds, which is why we use it here, but only the US generics have been reviewed by the FDA. Our Latisse vs bimatoprost guide explains what is the same and what is not.
Every bimatoprost lash product we sell, with price per bottle
The table lists each bimatoprost 0.03% product we sell for the lashes. "Smallest pack" is the cheapest way to try a product; "lowest per bottle" is the pack with the lowest price per bottle. All bottles are 3 mL. Prices are in US dollars, exclude shipping, and come from the live product catalogue as of 30 October 2026. Prices can change; the product page always shows the current price.
| Product | Strength | Maker / brand owner | Bottle | Smallest pack | Lowest per bottle | Lowest per mL |
|---|---|---|---|---|---|---|
| Careprost 3ml Eye Drops | 0.03% | Sun Pharmaceutical Industries | 3 mL | $9.00 for 1 | $9.00/bottle (sold by the bottle) | $3.00 |
| Latisse Generic 0.03% Eye Drop | 0.03% | Actiza Pharma Pvt. Ltd. | 3 mL | $40.00 for 5 ($8.00/bottle) | $5.50/bottle (40 for $220.00) | $1.83 |
| Lashona 3ml | 0.03% | Actiza Pharmaceutical (made for Actiza; plant not named) | 3 mL | $40.00 for 5 ($8.00/bottle) | $5.00/bottle (100 for $500.00) | $1.67 |
| Lashisma Eye Drop | 0.03% | Intas Pharmaceuticals Ltd | 3 mL | $42.00 for 2 ($21.00/bottle) | $16.67/bottle (6 for $100.00) | $5.56 |
Prices as of 30 October 2026. Per mL is the pack price divided by the number of bottles and by 3 mL. Latisse Generic and Lashona carry the Actiza name; SafeRxPills is run by Actiza Pharmaceutical Pvt. Ltd., so we have a direct interest in those two brands. "Latisse Generic" is our product name for an Indian bimatoprost 0.03% bottle; it is not an FDA-approved generic and is not made by AbbVie.
Which product to pick
All four contain bimatoprost 0.03% in a 3 mL bottle according to the product listings and cartons, so the choice comes down to maker, pack size and price:
- Careprost (Sun Pharma) is sold by the single bottle at $9.00, which suits a first try or a small top up.
- Lashona and Latisse Generic (Actiza) come in packs of 5 bottles or more, from $8.00 a bottle in the 5-bottle pack down to $5.00 to $5.50 in the largest packs. They suit someone who already knows bimatoprost suits them.
- Lashisma (Intas) costs more per bottle ($16.67 to $21.00) and comes in packs of 2, 4 or 6.
None of the four is the same product as Latisse. The Latisse label and trial results apply to Latisse; we use them on this page because they are the best published guide to how bimatoprost 0.03% is used on the lashes, not because the Indian brands were tested in that trial.
What a bigger pack does to the price
| Product | Pack sizes and prices (price per bottle) |
|---|---|
| Careprost 3ml | 1 bottle $9.00 |
| Latisse Generic 0.03% | 5 for $40.00 ($8.00); 10 for $75.00 ($7.50); 20 for $130.00 ($6.50); 40 for $220.00 ($5.50) |
| Lashona 3ml | 5 for $40.00 ($8.00); 10 for $70.00 ($7.00); 20 for $120.00 ($6.00); 40 for $230.00 ($5.75); 60 for $325.00 ($5.42); 80 for $420.00 ($5.25); 100 for $500.00 ($5.00) |
| Lashisma | 2 for $42.00 ($21.00); 4 for $70.00 ($17.50); 6 for $100.00 ($16.67) |
From the smallest to the largest pack, the price per bottle falls 37.5% for Lashona ($8.00 to $5.00), 31.25% for Latisse Generic ($8.00 to $5.50) and 20.6% for Lashisma ($21.00 to $16.67). Free shipping starts at $149: 17 bottles of Careprost ($153.00) or a 40-bottle pack of Latisse Generic ($220.00) or Lashona ($230.00) cross it, while the 20-bottle packs ($130.00 and $120.00) and the 6-bottle Lashisma pack ($100.00) do not.
How many bottles a course takes
The US Latisse 3 mL pack comes with 70 sterile applicators, and the label uses two a night (one per eye), so the pack is sized for 35 nights (our arithmetic). The Latisse trial ran for 16 weeks, or 112 nights, which is 3.2 such packs. If one of our 3 mL bottles lasts as long, four bottles cover the 16 weeks with some left over:
| Option | Four 3 mL bottles | What the figure is |
|---|---|---|
| Careprost, 4 single bottles | $36.00, plus $25 shipping = $61.00 | Our retail price, 30 October 2026 |
| Lashona or Latisse Generic, 5-bottle pack | $40.00 for 5, plus $25 shipping = $65.00 | Our retail price, 30 October 2026 |
| Brand Latisse 3 mL | About $491.64 (4 x $122.91) | What US pharmacies pay (NADAC), not the retail price |
| US generic bimatoprost eyelash solution 3 mL | About $319.52 (4 x $79.88) | What US pharmacies pay (NADAC), not the retail price |
The bottle count is an estimate: drops per bottle vary, and an opened bottle has a shelf life of its own. Results fade after stopping, so anyone who wants to keep the effect keeps applying it.
What US pharmacies pay for Latisse and its generics
NADAC (National Average Drug Acquisition Cost) is a weekly Medicaid survey of what US retail pharmacies pay to buy a medicine. It is not what a patient pays at the counter, which is usually higher, but it is a dated, public benchmark.
| Product (NADAC description) | Per mL | Per bottle |
|---|---|---|
| Latisse 0.03% eyelash solution, 3 mL (brand) | $40.97 | $122.91 |
| Latisse 0.03% eyelash solution, 5 mL (brand) | $31.53 | $157.65 |
| Bimatoprost 0.03% eyelash solution, 3 mL (generic, Sandoz and Alembic) | $26.63 | $79.88 |
| Bimatoprost 0.03% eyelash solution, 5 mL (generic, Sandoz and Alembic) | $20.57 | $102.85 |
NADAC 2026 file, latest week as of 28 October 2026 (rates effective 21 October 2026). Per bottle is per mL times bottle size. For prescriptions, coupons and whether insurance pays for Latisse, see our Latisse insurance and cost guide.
How the Indian brands compare with Latisse
Same molecule and strength, different product. The label lists Latisse as bimatoprost 0.3 mg/mL (0.03%) with benzalkonium chloride 0.05 mg/mL as the preservative, supplied with sterile, disposable applicators. The Indian brands state the same strength, but they are not tested by the FDA, and their inactive ingredients and packaging can differ. The biggest practical difference is the applicators: Latisse comes with them, and the standard Careprost pack is a dropper bottle without them. We have not confirmed that sterile applicators come with Lashona, Latisse Generic or Lashisma, so plan to buy sealed sterile single-use applicators separately. The Careprost vs Latisse guide covers the full comparison, and Lumigan vs Careprost explains how the glaucoma drop and the lash use relate.
How to apply it, from the Latisse label
- Start with a clean face, with makeup and contact lenses removed.
- Once nightly, place one drop on a sterile single-use applicator and apply it evenly along the skin of the upper eyelid margin at the base of the lashes. The lid should feel lightly moist without runoff.
- Blot any solution that runs beyond the upper lid margin with a tissue.
- Throw the applicator away after one use, and use a new sterile applicator for the other eye.
- Do not apply it to the lower lash line. Contact lenses can go back in 15 minutes later.
The label adds that more applications will not increase lash growth, and that if some solution gets into the eye it is not expected to cause harm and the eye should not be rinsed. The Latisse label says not to use any other brush or applicator; with a bottle that has no applicators, a sealed sterile single-use applicator is the nearest substitute, but that is outside the label. Never use a reusable makeup brush. Our step-by-step application guide goes through each step, including missed nights.
What results the label reports, week by week
The label trial was multicenter, double-masked, randomized and vehicle-controlled, with 278 adults treated for four months. The main measure was at least a 1-grade gain on the 4-point Global Eyelash Assessment (GEA) at week 16.
| Week | Latisse (n=137) | Vehicle (n=141) |
|---|---|---|
| 1 | 7 (5%) | 3 (2%) |
| 4 | 20 (15%) | 11 (8%) |
| 8 | 69 (50%) | 21 (15%) |
| 12 | 95 (69%) | 28 (20%) |
| 16 | 107 (78%) | 26 (18%) |
| 20 (4 weeks after stopping) | 103 (79%) | 27 (21%) |
The label says the onset is gradual and not significant in most patients until 2 months. Little changes in the first month. For a fuller timeline, read Careprost results week by week.
Length, fullness and darkness at week 16
| Week 16, mean change from baseline | Latisse | Vehicle |
|---|---|---|
| Lash length | 1.4 mm (25% increase), n=137 | 0.1 mm (2%), n=141 |
| Fullness or thickness | 0.7 mm2 (106% increase), n=136 | 0.1 mm2 (12%), n=140 |
| Darkness (intensity) | 18% darker, n=135 | 3% darker, n=138 |
The label reports darkness as intensity, where a negative value means darker lashes (minus 20.2, or minus 18%, for Latisse). After the 16 weeks, a 4-week follow-up period followed during which the effects started to return toward baseline.
What happens when you stop
The label says that on stopping, lash growth is expected to return to its pre-treatment level. The patient information says lashes are expected to return to their previous appearance over several weeks to months, any eyelid skin darkening is expected to reverse after several weeks to months, and any darkening of the iris is not expected to reverse and is likely permanent.
Side effects reported in the label
In the 278-adult trial, the most frequently reported adverse reactions were eye itching, eye redness (conjunctival hyperemia), skin darkening, eye irritation, dry eye symptoms and redness of the skin around the eye. The label says each occurred in less than 4% of patients; the patient information says itching and/or redness was reported in approximately 4%. Other reactions seen in the trials were a foreign body sensation, abnormal hair growth and darkening of the iris.
Since approval, voluntary reports have also included dry skin of the eyelid, eye or eyelid swelling, styes, local allergic reactions, watery eyes, temporary loss of a few lashes up to whole sections of lashes, and lash breakage, deepening of the eyelid crease with drooping lids (linked to loss of fat around the eye), rash, skin discoloration, peeling skin, ingrown lashes and blurred vision. The label notes these come from a population of uncertain size, so their frequency is not known. Our lash serum safety guide compares bimatoprost with cosmetic lash serums.
Who should not use bimatoprost on the lashes, and who should check first
- Contraindicated: the label says Latisse is contraindicated in people with hypersensitivity to bimatoprost or to any of the ingredients.
- Glaucoma or eye pressure treatment: if you use any eye-pressure (glaucoma) drops, especially Lumigan or other prostaglandin drops, or have ever had abnormal eye pressure, the label patient information says to use Latisse only under the close supervision of your doctor. Using it alongside prostaglandin drops may interfere with the pressure lowering, and the prescribing information says these patients should be monitored for changes in eye pressure. Tell anyone who checks your eye pressure that you use it.
- Inflammation inside the eye: use with caution in active intraocular inflammation such as uveitis, because it may get worse.
- Macular edema risk: use with caution after cataract surgery without a natural lens, with a torn posterior lens capsule, or with known risk factors for macular edema.
- Pregnancy: the label says it should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. For breastfeeding, it says it is not known whether enough is absorbed to reach breast milk.
- Eye problems while using it: seek a doctor's advice at once about continuing if you get an eye injury or infection, a sudden drop in vision, eye surgery, or any eye reaction, especially conjunctivitis or eyelid reactions.
Label warnings: iris color, lid darkening and stray hair
- Iris color: increased brown pigmentation of the iris has occurred with bimatoprost and is likely to be permanent. It may not be noticeable for several months to years.
- Eyelid skin: bimatoprost can darken the skin around the eye and the lashes. The darkening increases as long as it is used and has been reported to reverse after stopping in most patients.
- Hair where it should not grow: hair can grow where the solution repeatedly touches the skin, which is why the label says to apply it only to the upper lid margin and to blot any excess so it does not run onto the cheek.
- Uneven lashes: the two eyes can differ in lash length, thickness, color, number or direction of growth. These changes are likely to reverse after stopping.
Contamination, applicators and contact lenses
The label says the bottle tip should not touch any other surface, because it could become contaminated, and that applicators are for one eye and then thrown away, since reuse increases the potential for contamination and infections. It notes reports of bacterial keratitis (a corneal infection) linked to multiple-dose eye products, and says serious infections may result from contaminated solutions or applicators. Latisse contains benzalkonium chloride, which may be absorbed by soft contact lenses and discolor them, so lenses come out before use and go back in 15 minutes later.
For glaucoma, not lashes: Lumigan and Careprost Plus
We also sell Lumigan 0.01% and Lumigan 0.03% (Allergan India) and Careprost Plus (bimatoprost with timolol, Sun Pharma). These are glaucoma eye drops, put into the eye on a doctor's instructions, and are not lash products. Careprost Plus contains timolol, a beta blocker with its own warnings. See our Lumigan glaucoma guide. Bimatoprost on the eyebrows is outside every label; bimatoprost for eyebrows sets out what the trials show.
Importing bimatoprost into the US: what the FDA says
The FDA's personal importation page (content current as of 18 August 2025) states: "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use because these products purchased from other countries often have not been approved by the FDA for use and sale in the U.S." It goes on: "If a drug is approved for use in another country but is an unapproved new drug in the U.S. it is illegal to import."
The page also says the FDA cannot guarantee the safety and effectiveness of medicine bought over the internet from foreign sources, and that it recommends only obtaining medicines from legal sources in the US. It describes limited situations in which FDA staff may consider a more permissive decision. FDA-approved Latisse and generic bimatoprost eyelash solutions are sold in US pharmacies, and the brands on this page are not FDA-approved. Whether a parcel is released is decided by FDA and customs staff. You are responsible for checking the rules that apply to you before ordering. The full source is the FDA personal importation page, and our guide Is Careprost legal in the USA? covers the prescription and counterfeit questions.
How ordering works on SafeRxPills
- Choose a product and pack. Each product page shows every pack size and its price.
- Check out. Enter your delivery details. You can upload a prescription at checkout (up to 3 files); a licensed pharmacist reviews prescriptions that customers upload. Bimatoprost is a prescription medicine in the US, and we recommend seeing a doctor or optometrist before a first use, especially if you have any eye condition.
- Choose how to pay. The checkout offers credit or debit card, cryptocurrency, or bank wire. For card, payment instructions are sent by email after you place the order, and the checkout says it never asks for card details on that page. For bank wire, bank details are sent after the order. For cryptocurrency, you go to a crypto payment page as soon as the order is placed; the checkout takes an extra 5% off orders paid in cryptocurrency.
- Dispatch. The shipping page says orders are processed within 24 to 48 business hours of payment verification, and tracking numbers are sent by email.
Shipping cost and delivery time to the US
| Item | What the site states |
|---|---|
| Shipping method | Standard registered shipping, with a tracking number |
| Cost | $25 flat rate; free on orders of $149 or more |
| Delivery time to the USA | 7 to 14 business days (major cities 7 to 10 days, rural areas 10 to 14 days) |
| Processing | 24 to 48 business hours after payment verification |
| Packaging | Plain packaging with no mention of the contents or company name on the outside |
| Customs fees | The recipient's responsibility, if any are charged |
| P.O. boxes | Accepted with standard registered mail |
The site says delivery times are estimates and may vary due to customs or carrier delays. The Latisse label gives storage at 2 to 25 °C (36 to 77 °F); once your parcel arrives, keep the bottles within that range. Full details are on the shipping page.
If a parcel is lost, damaged or refused by customs
The site says that if a parcel is lost or does not arrive within 30 business days, you can choose a free reshipment or a full refund. Under the returns and refund policy, if customs refuses entry and the parcel is not delivered, the order is refunded; damaged items and the wrong product are also covered, usually on photos alone. Delivery issues must be reported within 30 business days of the expected delivery date, and product quality issues within 7 days of receiving the order. Ordering errors after shipping and how well a medicine works for you are not covered, and the $25 shipping fee is not refunded unless the error was ours.
Who SafeRxPills is
SafeRxPills is run from India by Actiza Pharmaceutical Pvt. Ltd. of Surat, Gujarat. As the banner on our own pages says: "We are not licensed by the FDA." The bimatoprost brands we sell are Indian products that are not FDA-approved, and two of them (Lashona and Latisse Generic) carry the Actiza name. What you can check with us is what you can check with any seller: the maker, strength, batch number and expiry date that should be printed on the carton and bottle.
Checking what arrives
- The carton and bottle should name bimatoprost, the strength (0.03%), the manufacturer, a batch number and an expiry date, and these should match each other and the product you ordered.
- Check the seal is intact; the Latisse label also says the bottle must be kept intact during use and the tip should not touch any surface.
- Indian bottles do not look like brand Latisse, which the label describes as an opaque white bottle with a turquoise cap and comes with sterile applicators. A different bottle is normal for an Indian brand; a carton that claims to be AbbVie's Latisse but does not match that description is not.
- If anything does not match, do not use it. Photograph the parcel and contact support@saferxpills.com.
Related guides
- Careprost vs Latisse: what differs and what it costs
- How to apply Careprost and Latisse, step by step
- Careprost results week by week
- Is Careprost legal in the USA?
- Latisse vs bimatoprost: the difference
- Lumigan vs Careprost
- Are lash growth serums safe?
- Is Latisse covered by insurance?
- Eyelash growth: all treatment options
Sources
- LATISSE (bimatoprost ophthalmic solution) 0.03%, US prescribing information and patient information, AbbVie, DailyMed SPL version 25 (published 23 December 2025): sections 1, 2, 3, 4, 5, 6.1, 6.2, 8.1, 8.2, 11, 14 (Tables 2 and 3), 16 and 17. DailyMed
- US Food and Drug Administration. Personal Importation (content current as of 18 August 2025). FDA
- openFDA Drugs@FDA API, searched 30 October 2026: NDA 022369 (Latisse, AbbVie, approved 24 December 2008); bimatoprost 0.03% topical ANDAs 202719 (Sandoz), 210515 (Alembic), 201894 (Apotex, discontinued), 203051 (Hikma, discontinued). openFDA
- Centers for Medicare and Medicaid Services. National Average Drug Acquisition Cost (NADAC) 2026 weekly file, as of 28 October 2026: LATISSE 0.03% EYELASH SOLUTION and BIMATOPROST 0.03% EYELASH SOLN. data.medicaid.gov
- SafeRxPills product catalogue, checkout, how ordering works, shipping page and returns and refund policy, as of 30 October 2026.
This page is for information and is not medical or legal advice. Bimatoprost is a prescription medicine in the US; speak to a doctor, optometrist or pharmacist before using it.
